Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNIS

Molecular Therapy

Volumn 19, Issue 4, 2011, Pages 629-631

  Rajecki, Maria ^a   Kangasmäki, Aki ^b   Laasonen, Leena ^b   Escutenaire, Sophie ^a   Hakkarainen, Tanja ^a   Haukka, Jarmo ^c   Ristimäki, Ari ^d   Kairemo, Kalevi ^b   Kangasniemi, Lotta ^e   Kiljunen, Timo ^b   Joensuu, Timo ^b   Pesonen, Sari ^a   Hemminki, Akseli ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b International Comprehensive Cancer Center Docrates   (Finland)

^c MAP Medical Technologies Oy   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Oncos Therapeutics   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; IODINE 123; ONCOLYTIC ADENOVIRUS; PACLITAXEL; PERTECHNETIC ACID TC 99M; SODIUM IODIDE SYMPORTER; TOPOTECAN;

ADENOVIRUS; ADULT; ANOREXIA; ANTIBODY TITER; BONE METASTASIS; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DYSPNEA; FEMALE; GENE DOSAGE; HUMAN; LEG EDEMA; LETTER; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; PELVIS TUMOR; PROTEIN EXPRESSION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UTERINE CERVIX CARCINOMA; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 79953299315     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.31     Document Type: Letter

References (17)

1. Barton, KN, Stricker, H, Brown, SL, Elshaikh, M, Aref, I, Lu, M et al. (2008). Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 16: 1761-1769.
2. Barton, KN, Tyson, D, Stricker, H, Lew, YS, Heisey, G, Koul, S et al. (2003). GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol Ther 8: 508-518. (Pubitemid 37161473)
3. Dingli, D, Diaz, RM, Bergert, ER, O'Connor, MK, Morris, JC and Russell, SJ (2003). Genetically targeted radiotherapy for multiple myeloma. Blood 102: 489-496. (Pubitemid 36841965)
4. Hakkarainen, T, Rajecki, M, Sarparanta, M, Tenhunen, M, Airaksinen, AJ, Desmond, RA et al. (2009). Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clin Cancer Res 15: 5396-5403.
5. Barton, KN, Freytag, SO, Nurushev, T, Yoo, S, Lu, M, Yin, FF et al. (2007). A model for optimizing adenoviral delivery in human cancer gene therapy trials. Hum Gene Ther 18: 562-572. (Pubitemid 47036049)
6. Peerlinck, I, Merron, A, Baril, P, Conchon, S, Martin-Duque, P, Hindorf, C et al. (2009). Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res 15: 6595-6601.
7. Merron, A, Baril, P, Martin-Duque, P, de la Vieja, A, Tran, L, Briat, A et al. (2010). Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. Eur J Nucl Med Mol Imaging 37: 1377-1385.
8. Cerullo, V, Pesonen, S, Diaconu, I, Escutenaire, S, Arstila, PT, Ugolini, M et al. (2010). Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 70: 4297-4309.
9. Koski, A, Kangasniemi, L, Escutenaire, S, Pesonen, S, Cerullo, V, Diaconu, I et al. (2010). Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 18: 1874-1884.
10. Nokisalmi, P, Pesonen, S, Escutenaire, S, Särkioja, M, Raki, M, Cerullo, V et al. (2010). Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 16: 3035-3043.
11. Pesonen, S, Nokisalmi, P, Escutenaire, S, Särkioja, M, Raki, M, Cerullo, V et al. (2010). Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 17: 892-904.
12. European Commission, Directorate General for Health and Therapeutics. Advanced Therapies.http://ec.europa.eu/health/human-use/advancedtherapies/ index-en.htm
13. Hemminki, A, Kanerva, A, Kremer, EJ, Bauerschmitz, GJ, Smith, BF, Liu, B et al. (2003). A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 7: 163-173. (Pubitemid 36395351)
14. Kirn, D (2001). Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 1: 525-538. (Pubitemid 33768667)
15. Dix, BR, Edwards, SJ and Braithwaite, AW (2001). Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol 75: 5443-5447. (Pubitemid 32488136)
16. Freytag, SO, Rogulski, KR, Paielli, DL, Gilbert, JD and Kim, JH (1998). A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323-1333. (Pubitemid 28312897)
17. Dias, JD, Liikanen, I, Guse, K, Foloppe, J, Sloniecka, M, Diaconu, I et al. (2010). Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res 16: 2540-2549.